In two decisions rendered on February 1st, 2023, the French Supreme Court (\u201cCour de cassation\u201d) overturned the decisions of the Paris Court of Appeal which had confirmed the rejections by the French PTO (\u201cINPI\u201d) of the supplementary protection certificate (\u201cSPC\u201d) applications for nivolumab and pembrolizumab.<\/p>\n
<\/p>\n
On this occasion, the Supreme Court clarified the interpretation of Article 3 a) of Regulation (EC) No. 469\/2009 (the \u201cSPC Regulation\u201d), i.e., when to consider whether a product is protected or not by a basic patent if it is only claimed in a functional manner in the said patent, that is without being expressly named or identified structurally. The adopted approach is in line with the one already used by the Paris Court of Appeal in the avelumab case.<\/p>","protected":false},"excerpt":{"rendered":"
Par deux arr\u00eats rendus le 1er\u00a0f\u00e9vrier 2023, la Cour de cassation a cass\u00e9 les arr\u00eats de la Cour d\u2019appel de Paris qui avaient confirm\u00e9 les rejets par l\u2019INPI des certificats compl\u00e9mentaires de protection (\u00ab\u2009CCP\u2009\u00bb) relatifs aux nivolumab et pembrolizumab. \u00c0 cette occasion la Haute juridiction a clarifi\u00e9 l\u2019interpr\u00e9tation de l\u2019article\u00a03 a) du r\u00e8glement (CE) n\u00b0 […]<\/p>","protected":false},"author":5,"featured_media":7959,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[27,28],"tags":[],"class_list":["post-7965","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-certificat-complementaire-de-protection","category-pharmaceutique"],"acf":[],"yoast_head":"\n